Vivani Medical Inc
VANI
Company Profile
Business description
Vivani Medical Inc is a clinical-stage biopharmaceutical company whose primary focus is the development of miniature subdermal drug implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases with once or twice-yearly administration. Its flagship drug implant candidates are designed to improve medication adherence and provide smooth, consistent therapeutic levels of GLP-1, the same class of active pharmaceutical ingredients used in Ozempic, Trulicity, and Wegovy.
Contact
1350 South Loop Road
AlamedaCA94502
USAT: +1 415 506-8462
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
36
Stocks News & Analysis
stocks
What Q4 US earnings did and didn’t tell us about AI and the outlook for tech shares
Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.
stocks
Top stocks of the year: Which opportunities remain in 2026?
A deep dive into the most traded stocks by Aussies in 2025 - and what this signals for the year ahead.
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,085.10 | 36.30 | 0.40% |
| CAC 40 | 7,993.49 | 52.31 | -0.65% |
| DAX 40 | 23,591.03 | 224.72 | -0.94% |
| Dow JONES (US) | 47,501.55 | 453.19 | -0.95% |
| FTSE 100 | 10,284.75 | 129.19 | -1.24% |
| HKSE | 25,757.29 | 435.95 | 1.72% |
| NASDAQ | 22,387.68 | 361.31 | -1.59% |
| Nikkei 225 | 55,620.84 | 342.78 | 0.62% |
| NZX 50 Index | 13,519.35 | 98.54 | -0.72% |
| S&P 500 | 6,740.02 | 90.69 | -1.33% |
| S&P/ASX 200 | 8,851.00 | 25.80 | 0.29% |
| SSE Composite Index | 4,124.19 | 15.63 | 0.38% |